Cerep offers preclinical drug discovery services for in vitro pharmacology, in vitro ADME-Tox & in vivo pharmacokinetics, and provides solutions allowing faster and cost-effective drug discovery by identifying at early stages the most promising drug candidates as well as eliminating those compounds likely to fail in development.
Cerep has developed unique know-how based on technologies of in vitro screening and of profiling using its proprietary database BioPrint®, which allows the modeling of clinical effects of drug candidates from their molecular properties.
The strength of our services also originates from our in-house production of biological material or from established partnerships with renowned reagents providers (such as PerkinElmer). Cerep’s technologies benefit to more than 460 pharmaceutical and biotechnological companies worldwide including most of the top pharmaceutical firms.
Cerep’s next objective is to open satellite laboratories, closer to where compounds are synthesized and drug candidates optimized, thus further decreasing turnaround time for data generation and delivery to discovery teams.
The success of this endeavour can only be achieved through the provision of consistent high quality data – reason for Cerep’s permanence – wherever the screening is performed.

Broad profiling/screening services
Cerep’s broad profiling/screening services can help you navigate toward more efficient drug discovery. They include:
    Assay design
    Assay development/transfer
    Compound management
    High throughput screening
    High throughput profiling
    Fast turnaround selectivity screening
Cerep’s platforms cover a wide range of target classes including ADME-Tox related targets; peptide and non peptide GPCRs; various enzymes, transporters, nuclear receptors and ion channels; employing methods and assay types such as radioligand binding assays, calcium mobilization and cAMP measurement using TRFRET, transporter/uptake assays, and bioluminescent and other fluorescent-based assays.
More than a hundred assays are developed each year, selected through various families to offer the most representative targets. They are either integrated in the Cerep catalog or are exclusively available to sponsor.
Advantages of our broad profiling/screening services include:
    Reproducibility – year after year – 20 years of experience.
    Low rejection rate allowing rapid delivery of results and rigorous quality control process
    Practical and operational innovation providing efficient custom oriented services (highly flexible and specialized teams and a lean organization)
    Excellent scientific support.

Assay design and development
Our customized assay development services include a full range of assays and technologies adapted to clients' specific projects and needs. Whether performing a million-compound primary screening, or secondary profiling of hits or lead candidates, you need tools that support the prediction of human biology. Cerep has an extensive and integrated suite of core competencies that will be valuable to your drug discovery programs.